Medpace Holdings, Inc. reported an insider ownership change involving Cornelius P. McCarthy III, with a transaction date of June 30, 2026. The filing relates to Medpace common stock and appears to reflect the scheduled vesting of restricted stock units rather than an open-market purchase or sale. The key security described is a restricted stock unit, or RSU, with each RSU representing a contingent right to receive one share of Medpace common stock. According to the explanatory note, McCarthy was granted 113 RSUs on November 28, 2025. Those units were scheduled to vest in four approximately equal installments on March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026. The June 30, 2026 report date corresponds to the second scheduled vesting date under that grant. Because the grant covers 113 RSUs over four approximately equal installments, the vested tranche would represent roughly one-quarter of the award, though the provided filing text does not state the exact number of shares that vested on this date. The filing also does not disclose a transaction price, which is consistent with RSU vesting being a compensation-related equity event rather than a cash market transaction. No transaction code, post-transaction beneficial ownership total, or separate open-market sale or purchase details are included in the provided document text. The filing was signed on July 2, 2026, by Stephen P. Ewald as attorney-in-fact for Cornelius P. McCarthy III. Overall, the filing reports an insider equity compensation event tied to a previously disclosed RSU award, marking continued vesting of Medpace common stock rights under McCarthy’s November 2025 grant.